Top 50 Biotech VC Funds & Investors in Australia (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Uniseed
VC Fund
|
26 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Manufacturing | $471k–$22M |
|
Uniseed Ventures
VC Fund
|
18 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Health Care, Manufacturing | $381k–$16M |
|
Brandon Capital
VC Fund
|
17 | Australia, United Kingdom, United States | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $673k–$81M |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
11 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.3M–$16M |
|
Main Sequence Ventures
VC Fund
|
10 | Australia, United States, Philippines | Seed, Series A, Series B | Software, Artificial Intelligence, Manufacturing | $1M–$73M |
|
Stoic VC
VC Fund
|
8 | Australia, United States, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | $600k–$16M |
|
Melbourne Angels
VC Fund
|
6 | Australia, United States, New Zealand | Angel, Seed | Biotechnology, Information Technology, Energy | $34k–$1.3M |
|
Artesian VC
VC Fund
|
6 | Australia, United States, Hong Kong | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Health Care | $40k–$15M |
|
Sydney Angels
VC Fund
|
5 | Australia, United States | Seed, Angel, Pre-Seed | Software, SaaS, Health Care | $120k–$1.5M |
|
Horizons Ventures
VC Fund
|
5 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Software, Artificial Intelligence | $1M–$110M |
|
OneVentures
VC Fund
|
4 | Australia, United States, Israel | Series A, Debt Financing | Software, Health Care, Biotechnology | $1M–$20M |
|
Brisbane Angels
VC Fund
|
4 | Australia, United States, New Zealand | Seed, Angel, Pre-Seed | Software, Biotechnology, Machine Learning | $120k–$1.3M |
|
IP Group Australia
VC Fund
|
4 | Australia, New Zealand | Seed, Series A, Pre-Seed | Biotechnology, Manufacturing, Renewable Energy | $811k–$29M |
|
Starfish Ventures
VC Fund
|
3 | United States, Australia, Philippines | Series A, Series B | Software, Enterprise Software, Internet | $2M–$18M |
|
GBS Ventures
VC Fund
|
3 | United States, Australia, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$55M |
|
Yuuwa Capital
VC Fund
|
3 | Australia | Series A, Seed, Series B | Biotechnology, Software, Analytics | $131k–$6.4M |
|
Grok Ventures
VC Fund
|
3 | Australia, United States, Singapore | Series A, Seed, Series B | Renewable Energy, Software, Biotechnology | $808k–$150M |
|
Possible Ventures
VC Fund
|
3 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $549k–$44M |
|
Clean Energy Finance Corporation
VC Fund
|
3 | Australia, United States, United Kingdom | Debt Financing, Series B | Energy, Renewable Energy, Real Estate | $5M–$333M |
|
QIC BioVentures
VC Fund
|
3 | Australia | Series A | Medical, Health Care, Biotechnology | |
|
Tin Alley Ventures
VC Fund
|
3 | Australia, Philippines | Pre-Seed, Seed | Biotechnology, Medical, Health Care | $2.6M–$3M |
|
Breakthrough Victoria
VC Fund
|
3 | Australia, United States, Philippines | Seed, Series A | Health Care, Manufacturing, Biotechnology | $708k–$36M |
|
Hitachi Ventures
VC Fund
|
2 | United States, Australia, United Kingdom | Series A, Series B, Series C | Software, Artificial Intelligence, Information Technology | $10M–$200M |
|
BridgeLane Capital
VC Fund
|
2 | Australia, Germany, United States | Seed, Series A | Software, Real Estate, Financial Services | $673k–$6M |
|
Folklore Ventures
VC Fund
|
2 | Australia, United States, New Zealand | Seed, Series A | Software, Information Technology, Apps | $500k–$21M |
|
Empath Ventures
VC Fund
|
2 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Health Care, Biotechnology, Personal Health | $100k–$12M |
|
Tenacious Ventures
VC Fund
|
2 | Australia, United States | Seed, Series A, Pre-Seed | Agriculture, AgTech, Farming | $942k–$49M |
|
Canaan Partners
VC Fund
|
2 | United States, United Kingdom, Israel | Series A, Series B, Series C | Software, Biotechnology, Health Care | $5M–$75M |
|
Vectr
VC Fund
|
2 | United States, Hong Kong, Singapore | Seed, Series A, Series B | FinTech, Financial Services, Artificial Intelligence | $547k–$70M |
|
UniQuest
VC Fund
|
2 | United Kingdom | Series B | Medical, Biotechnology | |
|
IP Group
VC Fund
|
2 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
South Australian Venture Capital Fund
VC Fund
|
2 | Australia | Seed, Series B | Health Care, Biotechnology, Internet of Things | $1M–$24M |
|
Hostplus
VC Fund
|
2 | Australia, United Kingdom, United States | Series A, Series B, Series C | Biotechnology, Software, Renewable Energy | $6.7M–$111M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Closed Loop Partners
VC Fund
|
2 | United States, United Kingdom, Canada | Seed, Series A | Recycling, Manufacturing, Artificial Intelligence | $2.4M–$16M |
|
Queensland Investment Corporation
VC Fund
|
2 | Australia, United States | Seed, Series A, Series B | Information Technology, FinTech, Software | $673k–$10M |
|
Monash University
VC Fund
|
2 | Australia | Series A, Seed | Biopharma, Therapeutics, Biotechnology | $17M–$19M |
|
The George Institute for Global Health
VC Fund
|
2 | Australia | Seed | Biometrics, Health Care, Biotechnology | |
|
Intermediate Capital Group
VC Fund
|
2 | United Kingdom, France, United States | Private Equity, Secondary Market, Series B | Biotechnology, Health Care, Information Technology | $49M–$439M |
|
Australian Medical Angels
VC Fund
|
2 | Australia, Hong Kong | Seed, Pre-Seed, Series A | Health Care, Machine Learning, Sports | |
|
Investible
VC Fund
|
2 | Australia, United States, Singapore | Seed, Series A, Pre-Seed | Software, Information Technology, FinTech | $250k–$20M |
|
Lowercarbon Capital
VC Fund
|
2 | United States, United Kingdom, France | Seed, Series A, Series B | Renewable Energy, Energy, Biotechnology | $3M–$150M |
|
Global Health Investment Fund (GHIF)
VC Fund
|
2 | United States, India, Austria | Series B, Series C | Health Care, Biotechnology, Medical Device | $4.5M–$18M |
|
Circulate Capital
VC Fund
|
1 | United States, India, Indonesia | Seed, Series B | Recycling, Biotechnology, Manufacturing | |
|
ATP Innovations
VC Fund
|
1 | Australia | Health Care, Biotechnology, Pharmaceutical | ||
|
Skalata
VC Fund
|
1 | Australia, United States, United Kingdom | Pre-Seed, Seed | Software, Information Technology, Marketplace | |
|
CP Ventures
VC Fund
|
1 | Australia, United States, India | Seed, Pre-Seed, Series A | Software, Science/Engineering, Data and Analytics | |
|
Catalio Capital Management
VC Fund
|
1 | United States, Israel, Switzerland | Series A, Series B | Biotechnology, Health Care, Therapeutics | |
|
VU Venture Partners
VC Fund
|
1 | United States, Colombia, India | Seed, Series A | Software, Health Care, Machine Learning | |
|
Plymouth Growth
VC Fund
|
1 | United States, Canada, Australia | Series A, Series B | Software, Information Technology, Enterprise Software | |
| Access all 256 VC funds in Australia Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 84
- Round size: Seed $600k–$3.5M; Series A $1.6M–$16M; Series B $471k–$22M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Lucia Bio — Lucia Bio is a biotechnology company that focuses on developing Syk inhibitors that help in the treatment of immunological diseases.
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $381k–$4.2M; Series A $1.3M–$16M
- Lead/follow: 12% lead, 88% follow
- Last fund: May invest from a new fund soon — raised $14M in 2017
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 61
- Round size: Seed $673k–$6.7M; Series A $4.9M–$81M; Series B $6.4M–$68M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $210M in 2019
Portfolio highlights
- Ena Respiratory — Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs.
- Allay Therapeutics — SUPPORTING PATIENTS THROUGH EVERY PHASE OF RECUPERATION The first technology designed to deliver weeks of localized pain management
- Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 25
- Round size: Series A $1.3M–$13M; Series B $6.4M–$16M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Denteric — Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Manufacturing
- Stage:Seed, Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 125
- Round size: Seed $1M–$7.1M; Series A $4.5M–$29M; Series B $13M–$73M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $303M in 2023
Portfolio highlights
- Endua — Endua is building the next generation of clean energy deep storage to power communities, remote industries and off-grid infrastructure at the flick of a switch - all day and night
- Arlula — Arlula provides a single integration point for a global network of satellite imagery. Sign up today and get BETA access to our API.
- QuintessenceLabs — Quantum cyberattacks can break current encryption in minutes! Get protected with QuintessenceLabs quantum key distribution, generation, and management.
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 24
- Round size: Seed $600k–$4.2M; Series A $7.6M–$16M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Ena Respiratory — Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs.
- Lenexa Medical — Lenexa Medical is an Australian based MedTech company.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.
Show more...Investment focus
- Industry: Biotechnology, Information Technology, Energy
- Stage:Angel, Seed
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 42
- Round size: Seed $34k–$1.3M; Angel $219k–$918k
- Lead/follow: 52% lead, 48% follow
Portfolio highlights
- Emanda — Emanda App helps business advisory firms and companies determine business value, auto-generate data rooms, set goals, and track progress daily via AI-driven tools.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
- Bitwise Agronomy — Bitwise Agronomy uses AI to analyze crop video footage and provide growers with insights into crop health, growth, and yield potential.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 227
- Round size: Seed $120k–$5M; Pre-Seed $40k–$1.5M; Series A $2.3M–$15M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- CUZIN — Providing a surprisingly human shopping experience. Trusted and secure. Millions of domains to choose from.
- Andromeda Robotics — At Andromeda, our personalised robot companions are helping Australian aged care teams bring joy and connection to residents to improve wellbeing.
- Infiction labs — SPARC 1.2 is a solar panel robotic cleaning system designed and developed by Infiction Labs Pvt Ltd for commercial solar plants.
Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.
Show more...Investment focus
- Industry: Software, SaaS, Health Care
- Stage:Seed, Angel, Pre-Seed
- Geography: Australia, United States
Investor stats
- Total investments: 94
- Round size: Seed $120k–$1.3M; Angel $130k–$890k; Pre-Seed $337k–$1.5M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Quizling — Quizling is an educational app that allows its users to make quick quizzes on their iPhone or iPad. Its users have the ability to plug their iPhone or iPad into their smart board or digital projector and challenge their class.Quizling is designed for teachers, students, and classrooms. Its aim is to make a teacher’s life easier, a student’slearning more interesting and challenging, and to help make the classroom a fun and engaging place. It can be used to preview a topic and check prior learning or before a test. Students also have the opportunity to make their own quizlings and challenge each other.Quizling was launched in 2012.
- ExtrasJar — Swap health insurance premiums for balanced investments and get access to your funds when using health services.
- Mary Technology — Generate detailed chronologies from documents in minutes with Mary Technology. Achieve 90%+ time reduction and ensure 99%+ accuracy. Try for free.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more...Investment focus
- Industry: Biotechnology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 250
- Round size: Seed $1M–$11M; Series A $6.2M–$50M; Series B $8M–$110M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Scopely — Scopely is a global interactive entertainment and mobile-first games company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Scrabble® GO,” “WWE Champions” and “Yahtzee® With Buddies,” among others. Scopely creates, publishes and live-operates immersive games that empower adirected-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami that supports one of the most diversified portfolios in the mobile games industry. Recognized multiple times as one of Fast Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has global operations across 17 markets (Asia-Pacific - Bangalore, Seoul, Shanghai, Singapore, Tokyo; EMEA - Barcelona, Dublin, Helsinki, Kyiv, London, Seville, Tel Aviv; North America - Boston, Boulder, Culver City, Mountain View, San Francisco), with additional game studio partners across four continents. For more information, visit www.scopely.com.
- Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
- Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!OneVentures is a later-stage venture capital firm focused on scaling Technology and Healthcare companies through growth equity and credit. The firm's role extends far beyond investment, as the firm actively guides companies toward achieving their next critical milestones. By leveraging decades of global experience and operational expertise,OneVentures accelerates growth and helps shape the future of its portfolio companies.A global growth focus drives their investment selection, with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Debt Financing
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 77
- Round size: Series A $1.5M–$20M; Debt Financing $1M–$6.7M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $145M in 2022
Portfolio highlights
- Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
- Kira Biotech — Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immunetolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.
Show more...Investment focus
- Industry: Software, Biotechnology, Machine Learning
- Stage:Seed, Angel, Pre-Seed
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 48
- Round size: Seed $120k–$1.3M; Angel $337k–$629k; Pre-Seed $200k–$1.3M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Giftbee — Giftbee is a B2B gifting marketplace with smart, eco-friendly solutions that enhance value and experience.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
- The Laundry Lady — The Laundry Lady is a mobile laundry service company that offers washing, ironing, pickup, and delivery services.
Ip Group Australia build and support outstanding intellectual property-based companies.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Renewable Energy
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, New Zealand
Investor stats
- Total investments: 15
- Round size: Seed $938k–$2.3M; Pre-Seed $811k–$942k; Series A $3M–$29M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- Hysata — Hysata is a developer of hydrogen electrolyzer designed to accelerate the world's shift away from fossil fuels to green hydrogen
- Additive Assurance — Additive Assurance offers quality assurance for metal additive manufacturing.
- Jetra Therapeutics — Jetra Therapeutics develops new treatment for obesity-related liver disease designed to reduce stress in liver cells.
Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more...Investment focus
- Industry: Software, Enterprise Software, Internet
- Stage:Series A, Series B
- Geography: United States, Australia, Philippines
Investor stats
- Total investments: 53
- Round size: Series A $2M–$6.6M; Series B $2.5M–$18M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $134M in 2008
Portfolio highlights
- Aktana — Build stronger relationships with HCPs using Aktana's artificial intelligence (AI) platform for life sciences to optimize omnichannel engagement.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,328,201 freelance designers compete to create amazing designs for your business. Start Today!
- Marani — Marani helps maternity providers quickly identify and manage maternal and fetal risk as well as empowering moms to have healthier pregnancies.
Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 39
- Round size: Series A $2.2M–$9M; Series B $8.8M–$35M; Series C $3M–$55M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
- Elastagen — Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen hasdeveloped a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.
- AirXpanders — AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Show more...Investment focus
- Industry: Biotechnology, Software, Analytics
- Stage:Series A, Seed, Series B
- Geography: Australia
Investor stats
- Total investments: 16
- Round size: Seed $131k–$808k; Series A $979k–$4.2M; Series B $2.6M–$6.4M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Nexgen Plants — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
- Icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
- Agworld — Agworld Farm Management software allows you to collect data at all levels and enables you to extract maximum value from this data; optimising profitability. The Agworld ecosystem is utilised by growers, agronomists and service providers on farms across the world.
Backing a better tomorrow
Show more...Investment focus
- Industry: Renewable Energy, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 66
- Round size: Seed $808k–$10M; Series A $3.3M–$63M; Series B $12M–$150M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Spriggy — Spriggy is a mobile app with a linked prepaid card that helps kids learn the concept of digital money.
- Airwallex — Established in Melbourne in 2015, Airwallex is a global payments fintech that enables businesses to operate anywhere, anytime.In today’s fast-changing digital era, Airwallex's purpose is to empower businesses of all sizes to grow without borders, and by doing so, contribute to the global economy. With technology at its core, Airwallex builta proprietary global financial infrastructure platform to help businesses transact, collect and pay in any foreign currency across 130+ countries and 50+ currencies, without the constraints of the traditional global financial system.
- August Robotics — August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 163
- Round size: Seed $1.6M–$10M; Pre-Seed $549k–$3.8M; Series A $9.5M–$44M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Eden Brew — Eden Brew is a ground-breaking new way to enjoy dairy products sustainably and nutritiously.
- Auriga Space — Next-generation space launch company providing frequent, sustainable and affordable transport to low Earth orbit
- InSpacePropulsion Technologies — Cost-effective, robust, and quickly available propulsion solutions, based on 10+ years of R&D and 40 years of combined experience in space propulsion.
The Clean Energy Finance Corporation invests using a commercial approach to overcome market barriers and mobilize investment in renewable energy, energy efficiency, and low emissions technologies. They seek to catalyze and leverage private sector funding for the commercialization and deployment of clean energy technologies necessary for thetransition to a carbon-constrained economy.
Show more...Investment focus
- Industry: Energy, Renewable Energy, Real Estate
- Stage:Debt Financing, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 118
- Round size: Series B $5M–$71M; Debt Financing $13M–$333M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $62M in 2018
Portfolio highlights
- Relectrify — Unlocking extra lifetime and performance of batteries via advanced battery management (BMS) technology.
- Wattwatchers — Be more energy efficient and maximise your renewable energy to save money, and the environment.
- Renewable Metals — Renewable Metals' unique alkali recycling process recovers critical minerals from old batteries so they can be used again and again.
QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Verva Pharmaceuticals — Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined productportfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
- Protagonist Therapeutics — Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Pre-Seed, Seed
- Geography: Australia, Philippines
Investor stats
- Total investments: 5
- Round size: Pre-Seed $2.6M–$3M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- i14 — We are i14 — we sit at the intersection of Computational Cognitive Science and AI research, and have developed a new class of models called Laplace Sequence Models that are an order of magnitude faster and more efficient and multiples more accurate than the transformer. We’ve also built a foundation model platform that allows organisations tocreate private, domain-specific expert models deployable across any environment (on-prem, at the edge, on device, in a private cloud, or hosted by i14). Our research lab continues to push beyond many of the limitations of current AI, and has a host of research projects which are continually integrated to update our foundation model platform. We recently closed a $4M initial round and are preparing for the next round.
- Mirugen — Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another.
- Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Seed, Series A
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 48
- Round size: Seed $708k–$7.1M; Series A $1.8M–$36M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- World View Enterprises — World View sets the standard for stratospheric exploration via remote sensing, C4ISR and asset monitoring via stratospheric balloons, along with future space tourism and research and education offerings.
- RayGen — We're powering the future with low cost, high efficiency solar power technology and renewable energy storage. Contact us for more details today.
- Conflux Technology — Conflux Technology is a new generation of heat exchangers made by metal additive manufacturing (3D printing).
Official website of Hitachi, Ltd. Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Series B, Series C
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 62
- Round size: Series A $10M–$50M; Series B $23M–$100M; Series C $30M–$200M
- Lead/follow: 19% lead, 81% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Arcee.ai — Learn how Arcee helps you build your own LLMs in your own cloud.
- Tem-Energy — Power, as it should be. We've reinvented how energy is bought and sold, so businesses pay less and generators earn more.
- Graphon — Graphon is a company that creates relational representation layers and pre-model intelligence for enterprise AI.
The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme
Show more...Investment focus
- Industry: Software, Real Estate, Financial Services
- Stage:Seed, Series A
- Geography: Australia, Germany, United States
Investor stats
- Total investments: 20
- Round size: Seed $673k–$4.2M; Series A $3M–$6M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- MadeComfy — Award-winning Airbnb management service in Australia and New Zealand. MadeComfy is a selected official partner of Airbnb. Find out how we earn you higher returns with short-term rentals.
- Futurerent — Futurerent is a tool that offers solutions to residential property investors for investment capital and cashflow needs.
- Evrima Technologies — Our clinical trial recruitment and management services put participants first. Trusted, timely clinical trial results are a good thing - for everybody.
Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.
Show more...Investment focus
- Industry: Software, Information Technology, Apps
- Stage:Seed, Series A
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 47
- Round size: Seed $725k–$5M; Series A $500k–$21M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Arkeus — Arkeus is a leader in the fusion of optics and autonomy. Our wide area autonomous optical systems are deployed to conduct Search, Intelligence, Surveillance and Reconnaissance in a range of operating environments.
- Hullbot — Hullbot is a developer of a robotic in-water cleaning system designed to inspect, map, and clean the hull of a boat without a human operator present. They offer design, development, and deployment of autonomous drones, delivering solutions to stop the growth of marine organisms, improve performance, and extend the time between haul-outs. Theirembedded intelligence enables their robots to interact with the environment on-the-fly.
- Sphere — Live courses led by vetted experts for professionals who want to advance their careers
Empath Ventures is a venture capital firm that mainly invests in psychedelic medicine companies. The firm specializes in the fields of investment financial services, finance, and venture capital. It was founded in 2021 and headquartered in Los Angeles California.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Personal Health
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 17
- Round size: Seed $100k–$12M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Xylo Bio — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
- Motif Neurotech — We're building DOT, a miniature brain stimulator designed to restore healthy brain activity in patients with treatment-resistant depression.
- Aperture Therapeutics — Aperture Therapeutics is building an innovative drug discovery platform that embraces the genetic diversity of patients and leverages mechanistic understanding of protective gene variants in the human population.
Tenacious Ventures - Australia's first and only dedicated agrifood tech VC firm.
Show more...Investment focus
- Industry: Agriculture, AgTech, Farming
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States
Investor stats
- Total investments: 23
- Round size: Seed $992k–$10M; Pre-Seed $942k–$2.2M; Series A $3.6M–$49M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- Cecil — From nature-based offset projects to biodiversity inventories, we simplify natural asset management for project developers, intermediaries, asset managers and investors.
- RapidAIM — RapidAIM is addressing the lack of information of pest threats to food crops. The company’s platform technology of low-power novel sensors plus edge computing offers a service to the agriculture industry of regional pest surveillance, crop border security, and pest forecasts.
- SwarmFarm Robotics — Global crop protection specialists ADAMA and Australian ag-tech company.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 655
- Round size: Series A $5M–$40M; Series B $7.8M–$75M; Series C $7.1M–$55M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Hermeus — Hermeus is developing hypersonic aircraft to connect the world faster than ever before.
- WorkMotion — WorkMotion offers Global HR Solutions to help companies navigate the New Ways of Working. Solutions fully compliant.
- Savvy — Savvy is a software development company that engages in cybersecurity.
Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.
Show more...Investment focus
- Industry: FinTech, Financial Services, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Hong Kong, Singapore
Investor stats
- Total investments: 74
- Round size: Seed $547k–$5.3M; Series A $1M–$37M; Series B $12M–$70M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
- Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
- MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
UniQuest is a university commercializing and technology transfer company.
Show more...Investment focus
- Industry: Medical, Biotechnology
- Stage:Series B
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
- Vicebio — Discover Sanofi's commitment to scientific innovation, our R&D focus areas, product pipeline, and digital approach to transforming the practice of medicine.
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 191
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Internet of Things
- Stage:Seed, Series B
- Geography: Australia
Investor stats
- Total investments: 13
- Round size: Seed $1M–$12M; Series B $13M–$24M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Seonix Bio — Seonix Bio is dedicated to helping health professionals, individuals and researchers understand glaucoma risk using genetics.
- Pearler.AI — Pearler gives your team super powers to respond fast to RFP, RFI, RFQ, Security, Cyber, Risk & Grant Questionnaires.
Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!
Show more...Investment focus
- Industry: Biotechnology, Software, Renewable Energy
- Stage:Series A, Series B, Series C
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 61
- Round size: Series A $6.7M–$49M; Series B $20M–$111M; Series C $13M–$60M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Myriota — Myriota delivers cutting-edge IoT technology through low-cost, low-power satellite connectivity for global remote monitoring.
- Cardiac Dimensions — Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
We Invest in the Circular Economy, a New Economic Model Focused on a Profitable and Sustainable Future.
Show more...Investment focus
- Industry: Recycling, Manufacturing, Artificial Intelligence
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 45
- Round size: Seed $2.4M–$6.7M; Series A $6M–$16M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $200M in 2022
Portfolio highlights
- Supersede — Looking for sustainable lightweight waterproof plywood alternative. Upgrade your marine and construction projects with Supersede eco friendly materials.
- EcoSpirits — The World's first low carbon, low waste spirits distribution technology. Join the revolution. End single use glass.
- Reterra — Save the environment with Reterra Corporation in Houston, TX. We recycle PET plastics into sustainable raw materials. Learn more on our site.
Queensland Investment Corporation is an investment company.
Show more...Investment focus
- Industry: Information Technology, FinTech, Software
- Stage:Seed, Series A, Series B
- Geography: Australia, United States
Investor stats
- Total investments: 24
- Round size: Seed $673k–$10M; Series A $3.4M–$10M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $17M in 2022
Portfolio highlights
- Gelomics — Gelomics operates as a biotechnology company. Gelomics provides 3D cell culture technologies.
- Paypa Plane — Future-focused payment systems that deliver benefits to banks, enterprises and payers. Working with existing systems to elevate legacy payment structures - Paypa Plane is ready to move the payment ecosystem forward.
- Pacific Energy — Our innovative energy solutions are transforming the way power is generated, delivered, and managed across the nation.
Monash University is an educational institution that offers undergraduate, graduate, and research courses in the fields of business, social sciences, science, and law. The schools of the university include Victorian College of Pharmacy, School of Nursing, and School of Applied Science.The university has a number of centers, five of which are inVictoria (Clayton, Caulfield, Berwick, Peninsula, and Parkville) and one in Malaysia. Monash also has a research and teaching center in Prato, Italy; a graduate research school in Mumbai, India; and a graduate school in Jiangsu Province, China.Monash University was founded in 1958 and is based in Melbourne, Australia.
Show more...Investment focus
- Industry: Biopharma, Therapeutics, Biotechnology
- Stage:Series A, Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Round size: Series A $17M–$19M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- ElectraLith — The cleanest, most versatile and most cost-efficient method of extracting and refining lithium, the primary element of a sustainable future.
- Atisama Therapeutics — RAGE Biotech is a biotechnology industry.
- Inosi Therapeutics — Inosi Therapeutics develop therapies to address fibrosis.
The George Institute is on a mission to improve the health of millions of people worldwide. Join us in our fight for a healthier world.
Show more...Investment focus
- Industry: Biometrics, Health Care, Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- CellSync — CellSync is a Biotechnology Research firm that is working to make changes in the Future of Cell Engineering.
- Sineva — Sineva is a medical device manufacturing firm that makes ultrasonography simulators.
- Neogenix Biosciences — NeoGenix Fertility: Selecting sperm for life through microfluidics and AI
We are a global alternative asset manager creating sustainable value by partnering with ambitious businesses
Show more...Investment focus
- Industry: Biotechnology, Health Care, Information Technology
- Stage:Private Equity, Secondary Market, Series B
- Geography: United Kingdom, France, United States
Investor stats
- Total investments: 40
- Round size: Series B $50M–$172M; Private Equity $49M–$439M
- Lead/follow: 73% lead, 27% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Draig Therapeutics — Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses.
- Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
- Excellera Advisory Group — Excellera Advisory Group is an Italian consultancy specializing in government affairs and reputation management.
Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.
Show more...Investment focus
- Industry: Health Care, Machine Learning, Sports
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, Hong Kong
Investor stats
- Total investments: 9
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- GXE — At GXE, our mission is to build the all-in-one platform for unlisted assets and funds management. We provide investors, fund managers, and family offices with the tools they need to succeed and enable them to focus on their portfolios and investors whilst GXE takes care of everything else. A licensed financial services company, GXE holdsAustralian Financial Services Licence 460870 issued by the Australian Securities and Investments Commission. GXE welcomes clients across sectors including corporate, family offices, pension and superannuation fund managers, private equity, property, and venture capital.
- Clean Slate Clinic — Clean Slate Clinic is a telehealth company that provides alcohol detox program who are struggling with alcohol.
- Neogenix Biosciences — NeoGenix Fertility: Selecting sperm for life through microfluidics and AI
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.
Show more...Investment focus
- Industry: Software, Information Technology, FinTech
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 169
- Round size: Seed $250k–$4.7M; Pre-Seed $404k–$2M; Series A $1.4M–$20M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Inspace XR — Inspire and engage prospective tenants, buyers, and your team with interactive virtual replicas of your assets, with 360 virtual tours, analytics & more.
- Directo — Directo operates as an independent B2B e-commerce pharmacy marketplace.
- EdenFarm Indonesia — EdenFarm Indonesia merupakan Start Up B2B, Pemasok bahan makanan mulai dari produk segar hingga sembako untuk restoran, warung nasi, hingga toko grosir.Menjual berbagai bahan pangan untuk usahamu mulai dari restoran hingga warung nasi
Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.
Show more...Investment focus
- Industry: Renewable Energy, Energy, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 189
- Round size: Seed $3M–$12M; Series A $11M–$50M; Series B $21M–$150M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $350M in 2022
Portfolio highlights
- Flair — Smart climate control in every room. Wireless smart thermostats and Smart Vents for Central Heating & AC, Mini Splits, Window ACs, Nest, Ecobee, and more
- Quilt — Quilt is the best home climate system available. Our electric, energy efficient heat pump uses smart technology to save homeowners money and cut emissions.
- Zap Energy — Zap Energy's fusion reactor stabilizes plasma using sheared flows rather than magnetic fields. Driving electric current through the flow creates the magnetic field, which confines and compresses the plasma. The higher the current, the greater the pressure and density in the plasma. Zap Energy's reactor is the least expensive, mostcompact, most scalable solution with the shortest path to commercially viable fusion.
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series B, Series C
- Geography: United States, India, Austria
Investor stats
- Total investments: 18
- Round size: Series B $7.5M–$18M; Series C $4.5M–$14M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $108M in 2012
Portfolio highlights
- PATH — We are a global team of innovators working to accelerate health equity so all people and communities can thrive.
- CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
- Themis Bioscience — Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing andacquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Circulate Capital is an impact-focused investment management firm dedicated to financing innovation, companies, and infrastructure that prevent the flow of plastic waste into the world's oceans and advance the circular economy.
Show more...Investment focus
- Industry: Recycling, Biotechnology, Manufacturing
- Stage:Seed, Series B
- Geography: United States, India, Indonesia
Investor stats
- Total investments: 17
- Lead/follow: no public data
Portfolio highlights
- Recykal — Recykal is a digital technology company powering a marketplace, building Saas, cloud based solutions for Waste management, recycling industry. Recykal also provides technology solutions for smart cities, municipal corporations and EPR services to FMCG, electronics companies
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- Ricron Panel — Manufacturer and supplier of high-quality building materials that are waterproof, rustproof, heat resistant, recyclable, lightweight, and fire retardant. We help businesses source sustainable materials for their operations.
ATP Innovations accelerates the growth of technology companies that target global markets, by providing advice and guidance from seasoned entrepreneurs, access to investors, customers and domain specialists, and world-class infrastructure tailored to the needs of startup companies. The ATP Innovations Accelerator HUB is home to Startmate, IgnitionLabs and university accelerator programs. ATP Innovations’ portfolio comprises over 65 companies from the software, hardware and life science sectors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Pharmaceutical
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- Clarity Pharmaceuticals — Clarity is a clinical stage company developing products to address the growing need for the use of radiopharmaceuticals in oncology.
Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.
Show more...Investment focus
- Industry: Software, Information Technology, Marketplace
- Stage:Pre-Seed, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 77
- Lead/follow: no public data
Portfolio highlights
- TALY — TALY is a platform that is designed to find, manage and retain employees from both perfromance and personality for business development.
- Viewa — Viewa is an augmented reality(AR) content publishing platform that brings print media such as magazines to life in 3D.
- Enrola — Looking for online training courses? Discover the perfect course for you with our easy course advisor quiz. Get individual guidance and apply directly.
CP Ventures is a VC fund that invests internationally in early stage, highly scalable, breakthrough technology companies driven by the 4IR
Show more...Investment focus
- Industry: Software, Science/Engineering, Data and Analytics
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, United States, India
Investor stats
- Total investments: 50
- Lead/follow: no public data
Portfolio highlights
- Tpaga — Tpaga is a mobile wallet for unbanked consumers in Latin America. Currently in Colombia and Mexico.In Latin America, more than 50% do not have credit cards or bank accounts, but what they do have is a cellphone. Tpaga allows consumers to store money via cash kiosk ( 4,000 in our network) and then use it to pay utility bills, cell phone top-up,supermarket and even gas station merchants. We have become the first mobile wallet in Latin America to allow consumers to pay groceries without having a bank account, and allowing unbanked commerces to start receiving payment without have POS systems.
- Anility — Embed financial health insights within your application using our world leading API service
- Ensuredit — ENSUREDIT enables and empowers end customers and Insurance Intermediaries with AI-based product platforms for transformational customer experience.
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, Israel, Switzerland
Investor stats
- Total investments: 91
- Lead/follow: no public data
Portfolio highlights
- PrognomiQ — PrognomiQ is invested in transforming the detection and early treatment of cancer and other complex diseases. Learn more about our test products and careers.
- Iambic — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
- Octant Bio — Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods toengineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases.
A multi-stage investment fund focused on Consumer, Enterprise, Fintech, Frontier, Healthcare, & PropTech
Show more...Investment focus
- Industry: Software, Health Care, Machine Learning
- Stage:Seed, Series A
- Geography: United States, Colombia, India
Investor stats
- Total investments: 85
- Lead/follow: no public data
Portfolio highlights
- Hadean — Hadean are a venture backed tech startup providing the most simple and secure platform for cloud native development. Intuitive and developer friendly, the Hadean Platform provides a friction free route to a cloud-native infrastructure. It lets you write applications once and deploy anywhere, taking care of setup, configuration, scaling, securityand more.Hadean have developed two flagship applications. Aether Engine provides distributed load balancing for agent-based simulations, while Muxer is a network model that utilises distributed edge networks. The result is spatial simulations of unparalleled size and complexity, where thousands of concurrent users can join and interact. Hadean have found traction in gaming, healthcare, virtual events and defence with industry leading companies such as Microsoft, Minecraft and CAE.
- MarketForce — MarketForce connects Africa’s informal retail outlets and consumers directly to suppliers of consumer goods and financial services by digitizing orders, delivery, and payments with the aim of solving the last mile distribution challenge.
- Dayta AI — SaaS Shopper Analytics - Cyclops presents you insightful data like shopper demographics, bahavioral metrics and many more. Drive more sales and traffic with AI now!
Growth Capital for Leading Midwest Tech Companies
Show more...Investment focus
- Industry: Software, Information Technology, Enterprise Software
- Stage:Series A, Series B
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 55
- Lead/follow: no public data
Portfolio highlights
- CloseSimple — CloseSimple is a real estate based software firm making conversation around buying or selling a house easier through Text Message & Email.
- Deck Commerce — Deck Commerce Order Management System (OMS) simplifies complex order processes to empower retailers to curate the best customer experience.
- Forj — Host your association's conferences, trade shows, or events on our highly customizable and interactive virtual event platform, backed by our customer success team.
Biotech VC funding in Australia at a glance
Stats across 279 deals from 256 investors.
Access all 256 VC funds in Australia Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech VC Funds in Australia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 256 VC funds investing in Australia Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!